The interest in LSD1 as a therapeutic target in cancer arose from the observation of its high-level expression in poor prognosis sub-groups of prostate, lung, brain, and breast cancer, as well as in certain hematologic malignancies (Maiques-Diaz & Somervaille, 2016). Here, KDM1A is linked to cancer.